Brevan Howard Sells Stake in Halozyme Therapeutics

Hedge fund decreases holdings in biopharmaceutical company by over 60%

Mar. 16, 2026 at 8:53am

Got story updates? Submit your updates here. ›

Brevan Howard Capital Management LP, a major investment firm, has decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 60.1% during the third quarter, according to a recent SEC filing. The fund now owns 64,217 shares of the biopharmaceutical company's stock, down from 161,023 shares previously.

Why it matters

This significant reduction in Brevan Howard's stake in Halozyme Therapeutics could signal a shift in the hedge fund's investment strategy or outlook on the company's prospects. As a major institutional investor, Brevan Howard's trading activity is closely watched by analysts and can influence market sentiment around the stock.

The details

According to the SEC filing, Brevan Howard sold 96,806 shares of Halozyme Therapeutics during the third quarter. The fund now owns 64,217 shares, or a 0.05% stake in the company, down from the previous 0.13% ownership. Halozyme Therapeutics is a biopharmaceutical company that specializes in drug delivery technologies, with a focus on enabling subcutaneous administration of biologic therapies.

  • Brevan Howard decreased its holdings in Halozyme Therapeutics during the third quarter of 2026.

The players

Brevan Howard Capital Management LP

A major global hedge fund that has decreased its stake in Halozyme Therapeutics by over 60%.

Halozyme Therapeutics, Inc.

A biopharmaceutical company that specializes in drug delivery technologies, including enabling subcutaneous administration of biologic therapies.

Got photos? Submit your photos here. ›

The takeaway

Brevan Howard's significant reduction in its Halozyme Therapeutics holdings could signal a shift in the hedge fund's investment strategy or outlook on the company's prospects, which may impact market sentiment around the stock going forward.